Yuhan Corp. (000100) - Total Assets
Based on the latest financial reports, Yuhan Corp. (000100) holds total assets worth ₩3.22 Trillion KRW (≈ $2.18 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 000100 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Yuhan Corp. - Total Assets Trend (2000–2025)
This chart illustrates how Yuhan Corp.'s total assets have evolved over time, based on quarterly financial data. See Yuhan Corp. book value and equity for net asset value and shareholders' equity analysis.
Yuhan Corp. - Asset Composition Analysis
Current Asset Composition (December 2025)
Yuhan Corp.'s total assets of ₩3.22 Trillion consist of 46.9% current assets and 53.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.8% |
| Accounts Receivable | ₩694.44 Billion | 21.6% |
| Inventory | ₩372.76 Billion | 11.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩184.67 Billion | 5.7% |
| Goodwill | ₩115.07 Billion | 3.6% |
Asset Composition Trend (2000–2025)
This chart illustrates how Yuhan Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 000100 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yuhan Corp.'s current assets represent 46.9% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2025, up from 5.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 21.6% of total assets.
Yuhan Corp. Competitors by Total Assets
Key competitors of Yuhan Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Yuhan Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 2.20 | 2.71 |
| Quick Ratio | 1.55 | 1.64 | 2.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩778.08 Billion | ₩741.12 Billion | ₩807.20 Billion |
Yuhan Corp. - Advanced Valuation Insights
This section examines the relationship between Yuhan Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 9.5% |
| Total Assets | ₩3.22 Trillion |
| Market Capitalization | $3.67 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Yuhan Corp.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Yuhan Corp.'s assets grew by 9.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Yuhan Corp. (2000–2025)
The table below shows the annual total assets of Yuhan Corp. from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩3.22 Trillion ≈ $2.18 Billion |
+9.48% |
| 2024-12-31 | ₩2.94 Trillion ≈ $1.99 Billion |
+4.61% |
| 2023-12-31 | ₩2.81 Trillion ≈ $1.91 Billion |
+13.73% |
| 2022-12-31 | ₩2.47 Trillion ≈ $1.68 Billion |
+0.36% |
| 2021-12-31 | ₩2.46 Trillion ≈ $1.67 Billion |
+2.94% |
| 2020-12-31 | ₩2.39 Trillion ≈ $1.62 Billion |
+13.05% |
| 2019-12-31 | ₩2.12 Trillion ≈ $1.43 Billion |
-2.60% |
| 2018-12-31 | ₩2.17 Trillion ≈ $1.47 Billion |
+3.78% |
| 2017-12-31 | ₩2.09 Trillion ≈ $1.42 Billion |
+2.38% |
| 2016-12-31 | ₩2.05 Trillion ≈ $1.39 Billion |
+8.81% |
| 2015-12-31 | ₩1.88 Trillion ≈ $1.27 Billion |
+16.36% |
| 2014-12-31 | ₩1.62 Trillion ≈ $1.10 Billion |
+6.74% |
| 2013-12-31 | ₩1.51 Trillion ≈ $1.03 Billion |
+7.90% |
| 2012-12-31 | ₩1.40 Trillion ≈ $950.85 Million |
+6.77% |
| 2011-12-31 | ₩1.31 Trillion ≈ $890.52 Million |
+4.66% |
| 2010-12-31 | ₩1.26 Trillion ≈ $850.84 Million |
+10.64% |
| 2009-12-31 | ₩1.13 Trillion ≈ $769.03 Million |
+9.23% |
| 2008-12-31 | ₩1.04 Trillion ≈ $704.04 Million |
+4.18% |
| 2007-12-31 | ₩997.19 Billion ≈ $675.78 Million |
+5.93% |
| 2006-12-31 | ₩941.40 Billion ≈ $637.97 Million |
+4.76% |
| 2005-12-31 | ₩898.67 Billion ≈ $609.01 Million |
+17.49% |
| 2004-12-31 | ₩764.90 Billion ≈ $518.36 Million |
+15.97% |
| 2003-12-31 | ₩659.58 Billion ≈ $446.99 Million |
+4.52% |
| 2002-12-31 | ₩631.04 Billion ≈ $427.64 Million |
+8.10% |
| 2001-12-31 | ₩583.76 Billion ≈ $395.60 Million |
+4.97% |
| 2000-12-31 | ₩556.14 Billion ≈ $376.89 Million |
-- |
About Yuhan Corp.
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and ana… Read more